Stifel Financial Corp Makes New Investment in Indivior PLC (NASDAQ:INDV)

Stifel Financial Corp acquired a new stake in Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,225 shares of the company’s stock, valued at approximately $100,000.

Several other hedge funds and other institutional investors have also modified their holdings of INDV. Melqart Asset Management UK Ltd purchased a new position in Indivior in the third quarter valued at approximately $132,000. Bank of New York Mellon Corp acquired a new stake in shares of Indivior in the second quarter worth $188,000. VELA Investment Management LLC purchased a new position in shares of Indivior in the 2nd quarter valued at $235,000. XTX Topco Ltd acquired a new position in shares of Indivior during the 2nd quarter valued at $249,000. Finally, Verition Fund Management LLC purchased a new stake in Indivior during the 3rd quarter worth $375,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INDV has been the topic of several research reports. Craig Hallum cut their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th. Piper Sandler reiterated an “overweight” rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Trading Down 1.6 %

NASDAQ INDV opened at $12.18 on Tuesday. The stock has a market cap of $1.68 billion, a P/E ratio of -304.42 and a beta of 0.75. The company’s fifty day simple moving average is $10.69 and its 200-day simple moving average is $11.45. The company has a current ratio of 0.83, a quick ratio of 0.65 and a debt-to-equity ratio of 23.50. Indivior PLC has a 52 week low of $7.33 and a 52 week high of $23.22.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $307.00 million for the quarter, compared to analyst estimates of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Equities research analysts predict that Indivior PLC will post 1.68 EPS for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.